

Summary Report of Consolidated Financial Results

For the Fiscal Year ended March 31, 2014



May 14, 2014
TSE/OSE-1st section

Company name: NIPRO CORPORATION

Code No.8086 URL: <http://www.nipro.co.jp/>

Representative: Yoshihiko Sano, President and Representative Director

Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division TEL: (06)6372-2331

Date of the ordinary general shareholders' meeting: June 26, 2014 Payment date of cash dividends: June 27, 2014

Filing date of annual reporting: June 26, 2014

Preparation of supplemental material on financial results: Yes

Presentation on annual results: Yes (for institutional investors and analysts)

(Note: Amounts are truncated to one million yen)

1. Consolidated Results for the Year ended March 31, 2014 (From April 1, 2013 to March 31, 2014)

(1) Consolidated Results of Operations

(Note: % of change from the previous fiscal year)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended March 31, 2014	300,752	24.8	12,289	8.1	11,918	(17.0)	2,861	(72.0)
Year ended March 31, 2013	241,020	13.7	11,370	(28.2)	14,363	19.9	10,231	123.1

Note: Comprehensive income Year ended March 31, 2014: 29,503 million yen (98.4%) Year ended March 31, 2013: 14,867 million yen (-%)

	Earnings per share	Diluted earnings per share	Ratio of net income to shareholders' equity	Ratio of ordinary income to total assets	Ratio of operating income to net sales
	Yen	Yen	%	%	%
Year ended March 31, 2014	18.19	16.29	2.3	2.0	4.1
Year ended March 31, 2013	59.99	54.12	8.9	2.7	4.7

Note: Equity in profit (loss) of affiliate Year ended March 31, 2014: - million yen Year ended March 31, 2013: (38) million yen

(2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Year ended March 31, 2014	619,654	135,960	20.2	832.14
Year ended March 31, 2013	579,302	128,763	20.7	703.47

Note: Equity Year ended March 31, 2014: 125,426 million yen Year ended March 31, 2013: 119,973 million yen

(3) Consolidated Cash Flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents
	Millions of yen	Millions of yen	Millions of yen	Millions of yen
Year ended March 31, 2014	21,552	(31,936)	(16,346)	70,892
Year ended March 31, 2013	22,593	(37,431)	23,359	92,622

2. Dividends

	Annual dividends per year					Annual total of dividends	Pay-out ratio (consolidated)	Ratio of dividends to net assets (consolidated)
	First-quarter	Second-quarter	Third-quarter	Year-end dividends	Annual dividends			
	Yen	Yen	Yen	Yen	Yen			
Year ended March 31, 2013	-	12.00	-	15.50	27.50	4,690	45.8	4.1
Year ended March 31, 2014	-	16.00	-	14.50	30.50	4,614	167.6	4.0
Year ending March 31, 2015 (Forecast)	-	13.50	-	13.00	26.50		59.6	

3. Forecast of Consolidated Financial Results for the Year ending March 31, 2015 (From April 1, 2014 to March 31, 2015)

	Net sales		Operating income		Ordinary income		Net income		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Six months ending Sept. 30 2014	155,000	8.1	7,800	34.5	6,300	8.9	2,150	(17.9)	14.26
Year ending March 31, 2015	330,000	9.7	20,000	62.7	16,700	40.1	6,700	134.1	44.45

(Note: The % displays in the line of six months ending Sept. 30, 2014 show increase/decrease ratio against the six months ended Sept. 30, 2013. The % displays in the line of Year ending March 31, 2015 show increase/decrease ratio against the year ended March 31, 2014)

4. Others

(1) Change in Significant Subsidiaries during the Current Period

(Change in specified subsidiaries caused a change in the scope of consolidation): No
 Additional: 0 Removal: 0

(2) Change in Accounting Policies and Accounting Estimate and Restatement

- [1] Changes in accounting policies by a newly issued accounting pronouncement : Yes
- [2] Changes other than [1] : No
- [3] Change in accounting estimate : No
- [4] Restatement : No

Note: Detailed information can be found in P.18 “(5) Notes to Consolidated Financial Statements (Changes in Accounting Policy)” in the attachment.

(3) Issued Shares (Common stock)

[1] Number of issued shares at end of the period (including treasury stock)

Year ended March 31, 2014: 171,459,479 shares Year ended March 31, 2013: 171,459,479 shares

[2] Number of treasury stock at end of the period

Year ended March 31, 2014: 20,730,973 shares Year ended March 31, 2013: 914,107shares

[3] Average number of shares during the period

Year ended March 31, 2014: 157,291,122 shares Year ended March 31, 2013: 170,545,769 shares

Note: Number of the stocks as of the year ended March 31 2014 included 1,187,500 shares owned by Trust Account E.

(Reference) Overview of the Unconsolidated Financial Results

1. Unconsolidated Results for the Year ended March 31 ,2014 (From April 1, 2013 to March 31, 2014)

(1) Results of Operations

(Note: % of change from the previous fiscal year)

	Net sales		Operating income		Ordinary income		Net income	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Year ended March 31, 2014	188,504	30.0	14,774	41.5	18,084	29.4	11,345	15.1
Year ended March 31, 2013	144,965	6.7	10,438	(6.1)	13,971	40.1	9,856	75.2

	Earnings per share	Diluted earnings per share
	Yen	Yen
Year ended March 31, 2014	72.13	64.58
Year ended March 31, 2013	57.79	52.13

(2) Financial Position

	Total assets	Net assets	Equity ratio	Net assets per share
	Millions of yen	Millions of yen	%	Yen
Year ended March 31, 2014	471,237	129,941	27.6	862.09
Year ended March 31, 2013	441,707	135,837	30.8	796.49

Note: Equity Year ended March 31, 2014: 129,941 million yen Year ended March 31, 2013: 135,837 million yen

*Information regarding the review procedure

This report is exempt from auditing procedure based on the Financial Instruments and Exchanges Act. It is under the auditing process at the time this report is disclosed.

*Disclaimer regarding projection information including appropriate use of forecasted financial result, and other special notes

- (1) The projection figures shown above are based on information that was available at the time of preparation and may contain certain uncertainties. Actual performance and other factors may differ from these projections due to changes in circumstances and other developments. More information concerning these forecasts can be found in P.2 “1.Business Result (1) Analysis Concerning Business Results”.

Table of Contents

1. Business Results	2
(1) Analysis Concerning Business Results	2
(2) Analysis Concerning Financial Position	3
(3) Basic Policies on Distribution of Profits and Dividends for Years ended March 31, 2014 and ending March 31, 2015	4
2. Corporate Group	4
3. Management Policies	6
(1) Basic Policies of Management	6
(2) Target Management Indicators	6
(3) Medium- to Long-term Management Strategies	6
(4) Issues and Challenges that the Group Faces	6
4. Consolidated Financial Statements	8
(1) Consolidated Balance Sheets	8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income	10
(3) Consolidated Statements of Shareholders' Equity	12
(4) Consolidated Statements of Cash Flows	14
(5) Notes to Consolidated Financial Statement	16
(Notes Related to Going Concern)	16
(Basis of Preparation for the Consolidated Financial Statements).....	16
(Changes in Accounting Policy).....	18
(Additional Information)	18
(Notes to the Consolidated Balance Sheets)	19
(Notes to the Consolidated Statements of Income)	19
(Notes to the Consolidated Statements of Shareholders' Equity)	19
(Segment Information)	20
(Per Share Information)	24
(Material Subsequent Event)	24
(Omission of Disclosures).....	24
5. Non-consolidated Financial Statements	25
(1) Non-consolidated Balance Sheets	25
(2) Non-consolidated Statements of Income and Non-consolidated Statements of Comprehensive Income	28
(3) Non-consolidated Statements of Shareholders' Equity	29
6. Others	32
(1) Changes in Directors	32

1. Business Results

(2) Analysis Concerning Business Results

[1] Commentary on Business Results

During the current period under review, the global economy exhibited a basic tone of moderate recovery overall. Signs of an upturn finally began to appear in Europe, and both stock prices and personal consumption held firm in the United States. In Japan, the effects of policies for monetary easing and economic stimulus brought a correction of the yen's appreciation and steady progress on the path to recovery. Nevertheless, the economic outlook remained clouded by some uncertainty because of apprehensions over the effects of the consumption tax hike and rise in prices for imported materials.

Under such circumstances, the Nipro Group continued its all-out efforts to expand sales, reduce production costs, and thereby improve its operating results.

As a result, consolidated sales for the current period under review increased by 24.8% from the previous year to 300,752 million yen. As for profit, consolidated operating income increased by 8.1% to 12,289 million yen, but consolidated ordinary income decreased by 17.0% to 11,918 million yen due to the decrease in foreign exchange gain and other non-operating income and increase in non-operating expenses. Consolidated net income decreased by 72.0% to 2,861 million yen due to a decrease in extraordinary income, increase in extraordinary loss, and increase in income taxes.

The overview of the results for the period under review by business segment is presented below.

In the period under review, the pharmaceutical product sales unit of Nipro Pharma Corporation was integrated into the Company's Domestic Division. In accordance with this change, the sales unit of Nipro Pharma Corporation, which had previously been categorized in the Pharmaceutical-Related segment, was placed in the Medical-Related segment. The year-on-year comparison, however, is not available, because it is difficult to make comparisons with the previous year based on the segments after the reclassification.

a. Medical-Related Business

In this segment, through the integration of our pharmaceutical product sales units in April 2013, we pursued synergistic effects as an all-around medical enterprise spanning the fields of medical equipment (Medical Sales Division) and drugs (Pharmaceutical Sales Division). We also became able to promptly provide a wide range of goods and services from the customer's perspective. Under these circumstances, the Medical Sales Division saw favorable sales of Heart Mate II (the implantable ventricular assisting device launched in April). Similarly, the existing cardiovascular (CVS) products such as extracorporeal ventricular assist devices posted substantial increases in both sales and profit.

In the field of vascular products, SeQuent® Please, the drug-eluting balloon catheter whose sales were launched in January 2014, traced favorable trends for both sales and profit thanks to collaboration with Goodman Co., Ltd. Sales of dialysis products (e.g., dialysis machines and HDF filters) and dialysis pharmaceuticals also increased greatly along with the spread of on-line HDF treatment. Sales also held firm for injection-transfusion products, enteral-alimentation products, and testing products. In the Pharmaceutical Sales Division, there was some hold-off from purchase before the April 2014 revision of pharmaceutical reimbursement prices, but there was more prevalent switching to generic drugs at DPC hospitals and dispensing pharmacies with an eye on the revision of diagnosis and treatment reimbursement accompanying official policy to promote use of generic drugs. This division as well consequently recorded favorable sales along with an increase in first-time adoption, chiefly of drugs for oral and external use.

Turning to overseas sales, profits greatly expanded because of the dramatic improvement in export payability under the influence of the yen's depreciation against the US dollar and Euro in the foreign exchange market. In addition, our setup for sales through local sales subsidiaries resting on local production for local consumption took root, allowing sales activities with close ties to the markets. As a reflection, firm sales were recorded for dialysis products such as dialyzers (artificial kidneys) as well as products for blood sugar level measurement.

As a result, net sales in this business came to 244,196 million yen.

b. Pharmaceutical-Related Business

In our Pharmaceutical-Related Business, we engaged in finely-tuned development of contracted business, through provision of various services in contracted development and support for addition of value in addition to the conventional contracted manufacturing. The period under review saw the launch of shipments of biosimilar preparations and anti-cancer agents, and strong sales of major generic drugs. We also promoted consigned sales based on joint development with the generic drug divisions and new drug development divisions of leading pharmaceutical companies inside and outside Japan.

Sales of pharmaceutical containers and devices related to pharmaceutical preparation and administration were strong because of our efforts to provide containers and systems suitable for each pharmaceutical product, address various needs on the medical care site for items such as small-volume bags for antimicrobial agents or osteoporosis drugs and materials for pre-filled syringes as well as rubber stoppers for pharmaceutical and vaccine use and containers for kit products. These containers and systems were developed by the Group or through joint development with pharmaceutical manufacturers based on our original processing technologies for plastics, rubbers, and metals. Furthermore, under governmental policy to curb medical expenses, we continued to work together with domestic and foreign pharmaceutical manufacturers for total lifecycle management of pharmaceutical products extending to future development of combination products, self-injection systems, and dosage form modification.

As a result, net sales in this business amounted to 51,507 million yen.

c. Glass-Related Business

Sales of tube glass for ampoules were on a par with those of the same period of the previous year. Although the domestic demand continued to decline, there was a slight upturn in orders from domestic glass-processing

companies. Sales of tube glass for vials also were up, thanks to an expansion of domestic sales driven by increased orders in connection with flu vaccines and antimicrobial preparations.

Sales of glass containers for medical recorded an overall increase from the same period of the previous year, because the decrease in domestic sales of existing products was more than offset by the increase in sales of imported vials for special preparations.

Among other glass-related products, sales of thermos bottles fell from the same period of the previous year due to a decline in export and sluggish domestic demand. Regarding glass for lighting purpose, demand for automotive electric lamp products continued in the trend of growth supported by the increased auto industry production, and this drove the increase in sales of all electric lamp glass products. Similarly, sales of tube glass for electric lamps increased along with the growth in demand for tube glass for lamps, and this translated into a sales increase for glass for lighting purpose as a whole.

As a result, net sales in this business totaled 4,776 million yen.

d. Other Business

In the other business, the sales from real estate rental income came to 271 million yen.

[2] Outlook for the next period

The outlook for the world economy includes expectations of a further upturn in Europe and continued firm growth in the United States. At the same time, however, it is difficult to foresee the influence of the consumption tax hike in Japan, and the situation is anticipated to remain one that will defy prediction. In this atmosphere, we in the Nipro Group will strive to improve our performance through continued approaches to preparation of an abundant assortment and development of products with high value-added levels.

We project the consolidated net sales of 330,000 million yen (up by 9.7% from the previous year), operating income of 20,000 million yen (up by 62.7% from the previous year), ordinary income of 16,700 million yen (up by 40.1% from the previous year), and net income of 6,700 million yen (up by 134.1% from the previous year), for the fiscal year ending March 31, 2015.

(2) Analysis Concerning Financial Position

[1] The conditions of assets, liabilities, and net assets

Total assets increased 40,352 million yen from the end of the previous year to 619,654 million yen. Current assets increased 8,145 million yen mainly due to the increase of 19,514 million yen in notes and accounts receivable-trade, and noncurrent assets increased 32,206 million yen mainly due to the increase of 12,446 million yen in building and structures.

Total liabilities increased 33,155 million yen from the end of the previous year to 483,694 million yen. Current liabilities increased 36,956 million yen mainly due to the increase of 14,895 million yen in current portion of convertible bond-type bonds with subscription rights to shares, and noncurrent liabilities decreased 3,801 million yen mainly due to the decrease of 14,900 million yen in convertible bond-type bonds with subscription rights to shares.

Total net assets increased 7,197 million yen from the end of the previous year to 135,960 million yen. Shareholders' equity decreased 19,302 million yen and accumulated other comprehensive income increased 24,756 million yen.

[2] The condition of cash flow

The ending balance of cash and cash equivalents in the period under review decreased 21,730 million yen from the previous year to 70,892 million yen.

(Cash flows from operating activities)

Net cash provided by operating activities was 21,552 million yen. The main accounts of cash inflow were income before income taxes and minority interests, 12,891 million yen and depreciation and amortization, 25,151 million yen. The main accounts of cash outflow were the increase of trade notes and accounts receivable, 10,729 million yen and payment of corporate income tax, 7,501 million yen.

(Cash flows from investing activities)

Net cash used in investing activities was 31,936 million yen. The main accounts of cash outflow were payments for purchase of noncurrent assets, 29,239 million yen.

(Cash flows from financing activities)

Net cash provided by financing activities was 16,346 million yen. The main accounts of cash inflow were proceeds from long-term loans payable, 63,280 million yen, and the main account of cash outflow was repayment of long-term loans payable, 49,028 million yen.

[3] Trend of the cash flow indicators

	The 58 th period Year ended March 31, 2011	The 59 th period Year ended March 31,2012	The 60 th period Year ended March 31,2013	The 60 th period Year ended March 31,2014
Shareholders' equity ratio (%)	22.4	22.0	20.7	20.2
Ratio of market value of shareholders' equity (%)	21.9	21.1	24.6	22.5
Debt redemption (years)	12.6	19.3	15.5	16.9
Interest coverage ratio	9.1	4.8	6.6	5.5

Note: Shareholders' equity ratio = Shareholders' equity / Total assets

Ratio of market value of shareholders' equity = Aggregate market value of the outstanding share / Total assets

Debt redemption = Interest-bearing liabilities / Cash flow from operating activities

Interest coverage ratio = Cash flow from operating activities / Interest payments

- Each indicator is calculated from consolidated financial data,
- Aggregate market value of the outstanding share is calculated as the share price at the fiscal year-end multiplied by the number of issued shares (excluding treasury stock)
- Cash flow from operating activities is taken from cash flows from operating activities on the consolidated statement of cash flows. Interest-bearing liabilities represent all liabilities on the consolidated balance sheets for which interest is payable. The amount of interest payments is taken from the payments of interests on the consolidated statement of cash flows.

(3) Basic Policies on Distribution of Profits and Dividends for years ended March 31, 2014 and ending March 31, 2015

We position profit return in the important management measure to distribute the non-consolidated net income to shareholders.

Retained earnings are to be invested in the sales and production facilities as well as in research and development, in view of enlarging the firm management basis and long-term business developments, so as to ensure stable and continuous growth.

According to the above-mentioned policy, annual dividends are calculated to be 30.50 yen per share. As we already paid interim dividends of 16.00 yen per share, year-end dividends are to be 14.50 yen per share to be proposed to the Company's 61th ordinary general meeting of shareholders.

Dividends for year ending March 31, 2015 are expected to be made under our basic policy of placing importance on profit return e.

2. Corporate Group

Our group consists of the Reporting Company ("the Company"), its 79 subsidiaries and 3 affiliated and is primarily engaged in manufacture and sale of medical equipment, pharmaceutical products and material products such as glass for medical purpose and glass for thermos bottles.

Positioning of each company in connection with the businesses of our group and the relation to the business segment are as follows:

<Medical-Related Business>

Domestic: The Company, Nipro Medical Industries Co., Ltd. and Goodman Co., Ltd. manufacture medical equipment, and the Company and Goodman Co., Ltd. sell medical equipment manufactured by its foreign subsidiaries.

Cell Science & Technology Institute, Inc., an affiliate company, develops, manufactures and sells cell-culture-related products.

Nichihos Co., Ltd. manages dispensing pharmacies and sells pharmaceutical products.

Overseas: Nipro (Thailand) Corporation Ltd. (Thailand), Nipro (Shanghai) Co., Ltd. (China) and Nipro Medical LTDA. (Brazil) purchase some of raw materials and machinery for their production from the Company, manufacture medical equipment, and sell through the Company and its subsidiaries as well as locally on their own.

Nipro Europe N.V. (Belgium), Nipro Medical Corporation (U.S.A.) and Nipro Trading (Shanghai) Co., Ltd. (China) and other sales subsidiaries purchase the products mainly from the Corporation and its subsidiaries, and sell medical equipment etc. in the areas of their locations.

Nipro Diagnostics, Inc. (U.S.A) manufactures and sells diabetes-related products. In addition, Nipro Tube Glass Pvt Ltd. (India), Nipro Glass Americas Corporation (U.S.A), Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd. (China), Jilin Nipro Jiaheng Pharmaceutical Packaging Co., Ltd. (China) and other subsidiaries manufacture and sell tube glass, vials and ampoules for medical purpose focusing on their each location.

<Pharmaceutical-Related Business>

The Company, Nipro Pharma Corporation, Zensei Pharmaceutical Industries Co., Ltd., Tohoku Nipro Pharmaceutical Corporation and Nipro Patch Co., Ltd. manufacture and sell pharmaceutical products. Yuki Gosei Kogyo Co., Ltd., an affiliated company, manufactures and sells active pharmaceutical ingredient etc.

< Glass-Related Business>

Domestic: The Company sells glass tube as well as manufactures and sells glass products.


Overseas: Shanghai Nissho Vacuum Flask Refill Co., Ltd. (China) sells internal glass sections of vacuum flask and other glass products..

<Other business>

The Company manufactures (purchases, in some cases) and sells production machinery for medical equipments and is engaged in leasing of real estate properties.

Nissho Insurance Services Co., Ltd. operates non-life insurance agency business mainly for the group companies.

The above explanations are illustrated as follows:



3. Management Policies

(1) Basic Policies of Management

Since our foundation of year 1954, the Company has a business philosophy of contribution to the society through corporate activities with the concept of “technology innovation”. In keeping with this philosophy, it has constantly sought to achieve growth through pursuit of distinctive products and technology for a higher quality of life (QOL) among patients and response to issues and needs on medical care sites.

In addition, considering the idea that the balance between “stability” and “growth” is most important for a company, we implement the “performance-linked remuneration system” that is the rule of profit sharing among shareholders, employees and management, and carry out active business operations, holding the employees responsible for boosting the performance of individual businesses.

(2) Target Management Indicators

Our performance targets were to achieve 1,000,000 million yen of consolidated net sales by the fiscal year 2030. And as a first step, we aim to achieve 500,000 million yen of consolidated net sales and 40,000 million yen of ordinary income by the fiscal year 2020. To realize these goals, we are going to move towards steady development in each field; medical, pharmaceutical, and glass businesses.

(3) Medium- to Long-term Management Strategies

Our basic policy and management strategy lie in expansion of share and sales in the global market by heightening our production capacity for products projected to exhibit quantitative growth, and providing products endowed with stable quality and cost competitiveness. We are also determined to develop products of value as viewed from the user's perspective by making effective use of our original technology and other management resources spanning the three business segments of medical equipment, drugs, and glass.

In our Medical-Related Business, to expand our share of the market, we are going to take vigorous action to fill out our assortment and open up new sales channels in domains such as diabetes-related and vascular-related products in addition to further developing our sales of the artificial kidney dialyzers (our mainstay products in this field) and other dialysis-related products. We aim to capture the leading share of the global market for dialysis-related products, and are going to construct a setup for manufacture and sales in various locations around the world, to realize the vision of local production for local consumption. In the field of generic drugs, the demand is expected to continue in a trend of rapid expansion, in light of the roadmap for promotion of their use presented by the Ministry of Health, Labour and Welfare, which hopes to increase the share of the total pharmaceutical sales volume occupied by generic drugs to at least 60 percent by the end of fiscal 2017. As such, besides our ongoing development of new generic drugs, we are going to continue concentrating on the construction of various sales routes to users such as DPC hospitals and dispensing pharmacy groups while pursuing greater synergistic effects through coordination with our sales division of medical equipment.

In the Contracted Manufacturing Division of our Pharmaceutical-Related Business, we are building setups for production and quality assurance to meet the needs of foreign firms as well. We are also augmenting our manufacturing facilities in domains with a high degree of difficulty (e.g., biomedicines) while further building up our business as one of the leading Japanese firms engaged in contracted manufacturing of pharmaceuticals. We are likewise working for the early start-up of production sites outside Japan in order to raise our stable supply capability and cost competitiveness even higher, and thereby enable supply of pharmaceuticals to the whole world.

In our Glass-Related Business too, we are using the store of glass processing technology accumulated over our long years of operation as the foundation for activities to develop high-quality containers for medical purpose and other items, and to expand their sales.

(4) Issues and Challenges that the Group Faces

In domestic sales in our Medical-Related Business, our Medical Sales Division shall strive to create designs reflecting consideration for medical safety and security and to develop products that alleviate environmental burden in the fields of products related to transfusion, diabetes, dialysis, vascular conditions, and CVS. It shall also mount approaches to develop products that are gentle to medical workers, patients, and the environment, while actively marketing and expanding sales of products addressing the diversifying needs and seeds in the market, to improve business results.

The Pharmaceutical Sales Division is faced with even more difficult circumstances in domestic business related to generic drugs. It shall endeavor to increase the brand power of Nipro as an all-around medical enterprise while continuing to heighten our presence in the market and strengthen price competitiveness. In overseas sales, its task is to further stabilize quality for products manufactured at our plants in India, Indonesia, and Bangladesh, which went into operation last fiscal year, and thereby to make a contribution to medical care sites in those countries with the high quality of products bearing the Nipro brand. There are prospects for a major increase in sales in Europe following the broadening of our assortment of dialysis-related products after acquisition of a German dialysis water treatment firm. In the United States, we have opened a strategic site in New Jersey, and are determined to expand sales by accurate response to needs for the kind of products sought on the front lines of medical care in that huge market. In our Pharmaceutical-Related Business, our main agendum is to achieve a rigorous reduction of manufacturing costs and increase our price competitiveness as the government accelerates deployment of measures to curb medical costs. With a view to supplying products to the global market, it is also essential for us to improve our setups for quality assurance in both the “soft” and “hard” aspects, in order to fully meet pharmaceutical quality standards in the United States and Europe. At the same time, we consider the construction of management to meet country risks at our overseas plants a

major task, and shall take action on it.

In our Glass-Related Business, we must fully apply our production engineering skills to build systems enabling stable production and sales of high-quality products. To this end, the job is to relocate our domestic glass processing plant to newly built quarters and expand the facilities. The new plant is to serve as the mother plant for all plants processing glass under the Nipro brand. On this basis, we shall make arrangements for provision of guidance regarding site expansion, facility expansion, and improvement of the manufacturing environment at glass processing plants in other countries. Meanwhile, we shall promote the standardization of high-quality glass products in the medical-use glass business of the Nipro Group and bolster arrangements for expansion of sales in the global market.

4. Consolidated Financial Statements
(1) [Consolidated Balance Sheets]

(Millions of yen)

	As of March 31, 2013	As of March 31, 2014
Assets		
Current Assets		
Cash and deposits	106,000	84,957
Notes and accounts receivable-trade	83,665	103,179
Merchandise and finished goods	53,899	59,517
Work in process	10,480	10,968
Raw materials and supplies	17,275	20,000
Deferred tax assets	5,375	7,354
Other	11,741	12,154
Allowance for doubtful accounts	(463)	(2,010)
Total current assets	287,974	296,119
Noncurrent assets		
Property, plant and equipment		
Buildings and structures	138,547	158,109
Accumulated depreciation and impairment loss	(69,911)	(77,025)
Buildings and structures, net	68,636	81,083
Machinery, equipment and vehicles	170,522	192,277
Accumulated depreciation and impairment loss	(117,991)	(135,012)
Machinery equipment and vehicles, net	52,530	57,265
Land	22,173	23,367
Lease assets	3,203	2,409
Accumulated depreciation	(2,029)	(1,507)
Lease assets, net	1,174	902
Construction in progress	23,786	20,534
Other	33,113	37,683
Accumulated depreciation and impairment loss	(26,712)	(29,242)
Other, net	6,400	8,440
Total property, plant and equipment	174,702	191,593
Intangible assets		
Goodwill	22,740	28,493
Lease assets	567	443
Other	10,958	13,278
Total intangible assets	34,265	42,216
Investments and other assets		
Investment securities	63,141	65,507
Net defined benefit asset	—	98
Deferred tax assets	8,805	8,453
Other	13,767	18,535
Allowance for doubtful accounts	(3,353)	(2,870)
Total investments and other assets	82,360	89,724
Total noncurrent assets	291,328	323,534
Total assets	579,302	619,954

(Millions of yen)

	As of March 31, 2013	As of March 31, 2014
Liabilities		
Current liabilities		
Notes and accounts payable-trade	40,878	45,661
Short-term loans payable	127,238	127,384
Commercial papers	10,000	10,000
Current portion of bonds	1,277	4,315
Current portion of Convertible bond-type bonds with subscription rights to shares	—	14,895
Lease obligations	1,011	949
Accounts payable-other	8,286	8,563
Accrued directors' bounuses	316	415
Income taxes payable	4,266	10,734
Provision for bounuses	2,810	3,516
Provision for directors' bounuses	70	123
Provision for loss on business liquidation	1,954	2,438
Notes payable-facilities	3,734	2,897
Other	11,912	18,820
Total current liabilities	213,758	250,714
Noncurrent liabilities		
Bonds payable	47,147	45,832
Convertible bond-type bonds with subscription rights to shares	14,900	—
Long-term loans payable	164,906	177,004
Lease obligations	2,040	1,510
Deferred tax liabilities	2,212	1,976
Provision for retirement benefits	2,854	—
Net defined benefit liability	—	4,042
Provision for directors' retirement benefits	742	449
Provision for loss on litigation	218	284
Other	1,757	1,878
Total noncurrent liabilities	236,780	232,979
Total liabilities	450,539	483,694
Net assets		
Shareholders' equity		
Capital stock	84,397	84,397
Capital surplus	636	688
Retained earnings	54,788	52,567
Treasury stock	(865)	(17,999)
Total shareholders' equity	138,957	119,654
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(12,547)	(7,443)
Deferred gains or losses on hedges	—	38
Foreign currency translation adjustment	(6,436)	13,535
Remeasurements of defined benefit plans	—	(357)
Total accumulated other comprehensive income	(18,983)	5,772
Minority interests	8,789	10,533
Total net assets	128,763	135,960
Total liabilities and net assets	579,302	619,654

(2) [Consolidated Statements of Income and Consolidated Statement of Comprehensive Income]
Consolidated Statements of Income

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Net sales	241,020	300,752
Cost of sales	175,314	213,220
Gross profit	65,706	87,532
Selling, general and administrative expenses	54,336	75,242
Operating income	11,370	12,289
Non-operating income		
Interest income	959	748
Dividends income	1,755	1,868
Foreign exchange gains	3,062	1,344
Other	1,231	1,793
Total non-operating income	7,010	5,754
Non-operating expenses		
Interest expenses	3,447	3,857
Share of loss of entities accounted for using equity method	38	—
Other	531	2,268
Total non-operating expenses	4,017	6,125
Ordinary income	14,363	11,918
Extraordinary income		
Gain on sales of noncurrent assets	54	242
State subsidy	764	1,549
Gain on sales of investment securities	4,167	1,321
Guarantee commission received	—	745
Other	245	282
Total extraordinary income	5,231	4,141
Extraordinary loss		
Loss on sales of noncurrent assets	5	181
Loss on retirement of noncurrent assets	368	408
Impairment loss	2	1
Loss on reduction of noncurrent assets	770	1,500
Settlement package	214	—
Provision for loss on business liquidation	—	483
Other	174	592
Total extraordinary losses	1,536	3,169
Income before income taxes and minority interests	18,058	12,891
Income taxes-current	6,865	13,739
Income taxes-deferred	574	(3,950)
Total income taxes	7,439	9,789
Income before minority interests	10,619	3,102
Minority interests in income	387	240
Net income	10,231	2,861

Consolidated Statements of Comprehensive Income

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Income before minority interests	10,619	3,102
Other comprehensive income		
Valuation difference on available-for-sale securities	(6,017)	5,103
Deferred gains or losses on hedges	—	38
Foreign currency translation adjustment	10,265	21,259
Total other comprehensive income	4,248	26,401
Comprehensive income	14,867	29,503
Comprehensive income attributable to shareholders of parent company	13,984	27,975
Comprehensive income attributable to minority interests	882	1,528

(3) [Consolidated Statements of Shareholders' Equity]

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Shareholder's equity		
Capital		
Balance at beginning of year	84,397	84,397
Increase (decrease) during the period		
Net increase (decrease) during the period	—	—
Balance at end of year	84,397	84,397
Capital Surplus		
Balance at beginning of year	636	636
Increase (decrease) during the period		
Disposal of treasury stock	(0)	52
Net increase (decrease) during the period	(0)	52
Balance at end of year	636	688
Earned surplus		
Balance at beginning of year	48,389	54,788
Increase (decrease) during the period		
Dividend of surplus	(4,007)	(5,054)
Net income	10,231	2,861
Change of scope of consolidation	320	—
Other	(144)	(27)
Net increase (decrease) during the period	6,399	(2,220)
Balance at end of year	54,788	52,567
Treasury stock		
Balance at beginning of year	(864)	(865)
Increase (decrease) during the period		
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,043
Net increase (decrease) during the period	(0)	(17,134)
Balance at end of year	(865)	(17,999)
Total Shareholders' equity		
Balance at beginning of year	132,558	138,957
Increase (decrease) during the period		
Dividend of surplus	(4,007)	(5,054)
Net income	10,231	2,861
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,096
Change of scope of consolidation	320	—
Other	(144)	(27)
Net increase (decrease) during the period	6,399	(19,302)
Balance at end of year	138,957	119,654

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Accumulated other comprehensive income		
Valuation differences on available-for-sale securities		
Balance at beginning of year	(6,528)	(12,547)
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	(6,018)	5,103
Net increase (decrease) during the period	(6,018)	5,103
Balance at end of year	(12,547)	(7,443)
Deferred gains or losses on hedges		
Balance at beginning of year	—	—
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	—	38
Net increase (decrease) during the period	—	38
Balance at end of year	—	38
Foreign currency translation adjustment		
Balance at beginning of year	(16,209)	(6,436)
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	9,772	19,971
Net increase (decrease) during the period	9,772	19,971
Balance at end of year	(6,436)	13,535
Remeasurements of defined benefit plans		
Balance at beginning of year	—	—
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	—	(357)
Net increase (decrease) during the period	—	(357)
Balance at end of year	—	(357)
Total accumulated other comprehensive income		
Balance at beginning of year	(22,737)	(18,983)
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	3,753	24,756
Net increase (decrease) during the period	3,753	24,756
Balance at end of year	(18,983)	5,772
Minority interests		
Balance at beginning of year	4,129	8,789
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	4,659	1,743
Net increase (decrease) during the period	4,659	1,743
Balance at end of year	8,789	10,533
Total net assets		
Balance at beginning of year	113,950	128,763
Increase (decrease) during the period		
Dividend of surplus	(4,007)	(5,054)
Net income	10,231	2,861
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,096
Change of scope of consolidation	320	—
Other	(144)	(27)
Net increase (decrease) of the items other than shareholders' equity during the period	8,413	26,500
Net increase (decrease) during the period	14,812	7,197
Balance at end of year	128,763	135,960

(4) [Consolidated Statements of Cash Flows]

	(Millions of yen)	
	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Net cash provided by (used in) operating activities		
Income before income taxes and minority interests	18,058	12,891
Depreciation	21,209	25,151
Impairment loss	2	1
Amortization of goodwill	2,834	4,827
Equity in (earnings) losses of affiliates	38	—
Increase (decrease) in allowance for doubtful accounts	193	1,072
Increase (decrease) in provision for retirement benefits	435	(3,070)
Increase (decrease) in net defined benefit liability	—	3,497
Interest and dividends income	(2,715)	(2,617)
Interest expenses	3,447	3,857
Foreign exchange losses (gains)	(1,693)	(2,997)
Loss (gain) on sales of investment securities	(4,164)	(1,160)
Decrease (increase) in notes and accounts receivable-trade	(8,965)	(10,729)
Decrease (increase) in inventories	(3,182)	(2,441)
Increase (decrease) in notes and accounts payable-trade	(830)	(2,467)
Decrease (increase) in other assets	518	2,061
Increase (decrease) in other liabilities	4,218	2,207
Other loss (gain)	156	157
Subtotal	29,561	30,240
Interest and dividends income received	2,720	2,665
Interest expenses paid	(3,439)	(3,908)
Other proceeds	361	685
Other payments	(322)	(630)
Income taxes paid	(6,287)	(7,501)
Net cash provided by (used in) operating activities	22,593	21,552
Net cash provided by (used in) investing activities		
Payments into time deposits	(6,514)	(6,553)
Proceeds from withdrawal of time deposits	14,290	7,678
Payments for purchase of investment securities	(12,025)	(1,139)
Proceeds from sales of investment securities	5,817	9,058
Payments for purchase of investments in entities accounted for using equity method	—	(2,502)
Payments for purchase of investments in resulting in change in scope of consolidation	(2,385)	(6,958)
Purchase of investment in subsidiaries resulting in change in scope of consolidation	3,215	—
Payments for investment in capital	(3,367)	(3,764)
Payments for purchase of noncurrent assets	(37,794)	(29,239)
Proceeds from sales of noncurrent assets	151	464
Payments for retirement of noncurrent assets	(96)	(104)
Proceeds from governmental subsidies for investment in property and equipment	53	1,112
Net decrease (increase) in short-term loans receivable	1,813	69
Payments of loans receivable	(518)	(183)
Proceeds from collection of loans receivable	148	126
Other payments	(347)	(5)
Other proceeds	128	4
Net cash provided by (used in) investment activities	(37,431)	(31,936)

	(Millions of yen)	
	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Net cash provided by (used in) financing activities		
Net increase (decrease) in short-term loans payable	9,444	(9,340)
Proceeds from long-term loans payable	61,629	63,280
Repayment of long-term loans payable	(43,039)	(49,028)
Proceeds from issuance of bonds	9,941	2,979
Redemption of bonds	(10,100)	(1,282)
Proceeds from stock issuance to minority shareholders	261	150
Decrease (increase) in treasury stock	(18)	—
Proceeds from sales of treasury shares	—	1,195
Purchase of treasury shares	—	(18,277)
Repayments of finance lease obligations	(750)	(967)
Cash dividends paid	(3,996)	(5,038)
Cash dividends paid to minority shareholders	(12)	(18)
Net cash provided by (used in) financing activities	23,359	(16,346)
Effect of exchange rate change on cash and cash equivalents	3,030	4,981
Net increase (decrease) in cash and cash equivalents	11,552	(21,749)
Cash and cash equivalents at beginning of period	79,449	92,622
Increase in cash and cash equivalents from newly consolidated subsidiary	1,620	19
Cash and cash equivalents at end of period	92,622	70,892

(5) Notes to Consolidated Financial Statement

(Notes Related to Going Concern)

N/A

(Basis of Preparation for the Consolidated Financial Statements)

1) Scope of consolidation

[1] Consolidated subsidiaries: 72

Name of representative consolidated subsidiaries,

- Nipro Medical Industries Co., Ltd.
- Nipro Europe N.V.
- Nipro Diagnostics, Inc.
- Tohoku Nipro Pharmaceutical Corporation
- Nipro India Corporation Pvt Ltd.
- Goodman Co.,Ltd.
- Nipro (Thailand) Corporation Ltd.
- Nipro Medical Corporation
- Nipro Pharma Corporation
- Nipro Patch Co.,Ltd.
- Nipro Medical (Hefei) Co., Ltd.

Nichihos Co., Ltd. and other 11 companies were acquired their shares and Salbego Laboratorio Pharmaceutico LTDA. and other 5 companies increased in materiality. For these reasons, those companies are included in scope of consolidation from the consolidated fiscal year 2013.

[2] Name of representative unconsolidated subsidiary

- Nipro Pharma Vietnam Co.,Ltd.

The unconsolidated subsidiaries are small-sized companies, whose combined total assets, net sales, net income and earned surplus in the aggregate (averaged for recent 5 years) are not material to the consolidated financial statements.

2) Application of equity method

[1] Number of affiliate accounted for by the equity method: 1

- Infraredx, Inc.

[2] Name of representative unconsolidated subsidiary not accounted for by the equity method:

- Nipro Pharma Vietnam Co.,Ltd.

Name of affiliate not accounted for by the equity method:

- Yuki Gosei Kogyo Co., Ltd.

The equity method is not applied to the unconsolidated subsidiaries and the affiliate company, since they are not material to the consolidated net income (amounts worth to equity) and earned surplus(amounts worth to equity) etc., either individually or in the aggregate.

3) Accounting period of consolidated subsidiaries

Among the main consolidated subsidiaries, accounts closing date of the foreign subsidiary is December 31. Consolidated financial statements as of that date are used in preparing for consolidated financial statements, and necessary adjustments are made to reflect significant transactions that occurred between December 31 and March 31.

4) Accounting principles and practices

[1] Valuation standards and methods for significant assets

Securities

Available-for-sale securities

Securities with market quotations ----- Valued at the market price quoted on the balance sheet date.
(Differences in valuation are presented as a component of shareholders' equity. Costs are determined by the weighted average method.)

Securities without market quotations ----- Valued at cost by the weighted average method

Inventories

Valued at cost by the weighted average method (Writing down method below cost to the net selling value for decreased profitability)

Derivatives transaction

Valued at the market price

- [2] Method of depreciation and amortization for significant depreciable assets
 Property, plant and equipment ----- Mainly Declining-balance method
 (Excluding lease assets) However, buildings acquired after April 1, 1998 (excluding attached structures), are depreciated by straight-line method.
 The foreign subsidiaries use straight-line method.
- Lease assets
 Lease assets under the finance lease transaction that does not transfer ownership
 ----- Recorded by straight-line method its useful lives are equals to the lease term and the residual values are equal to zero.
 We still have adopted the similar manner to an ordinary rental transaction for the finance lease transactions that do not transfer ownership and the starting dates of the lease transactions were before March 31, 2008.
- [3] Standards for recognition of significant allowances
- Allowance for double accounts ---- In order to cover the probable losses on collection, an allowance for doubtful accounts is provided for the estimated amount of uncollectible receivables. For general receivables, the amount of provision is based on historical write-off rates, and for the doubtful receivables, based on the specific collectability.
- Provision for bonuses ----- In order to cover the payment of bonuses to employees, an allowance is provided for the estimated amount of bonuses to be paid, prorated for the consolidated accounting period.
- Provision for directors' bonuses ---- In order to cover the payment of bonuses to directors and corporate auditors, an allowance is provided for the estimated amount of bonuses to be paid, prorated for the consolidated accounting period.
- Provision for loss on
 business liquidation ----- In connection with withdrawal from retail business which we sold the shares of the consolidated subsidiaries, the estimated loss at the end of the consolidated accounting period is posted for disposal of land, building and other properties to be sold accordingly.
- Provision for
 directors' retirement benefits ----- An allowance is provided for severance indemnity for directors and corporate directors based on the amounts to be paid at the end of the consolidated accounting period.
- Provision for loss on litigation ----- In order to cover the probable losses on lawsuit, an allowance for loss is provided for the estimated amount acceptable as needed.
- [4] Accounting Treatment of Retirement Benefits
 Method of attributing expected benefit to periods
 In calculating retirement benefit obligation, the Company attributed expected benefit to the periods on a straight-line basis.
- Accounting Method of Actuarial gains and losses and prior service costs
 Prior service costs are amortized on a straight-line basis over the certain period (generally 5 years) which is no longer than the expected average remaining working lives of the employees when they occur.
 Actuarial gains and losses are amortized on a straight-line basis over the certain period (generally 5years) which is no longer than the expected average remaining working lives of the employees from the following the year which they arise.
- [5] Amortization of goodwill
 Goodwill is amortized using the straight-line method over the estimated benefit period of the asset.
- [6] Range of cash and cash equivalent carried on the consolidated cash flow statement.
 Cash and cash equivalent carried on the cash flow statement consist of cash on hand, cash in banks that are able to withdraw as needed, and short-term investment that will be matured within three months after acquisition, easy to be converted into cash without much risks from fluctuation of prices.
- [7] Significant method of hedge accounting
 Method of hedge accounting
 The deferral hedge accounting method is applied in principle. Designation accounting is used for foreign exchange swap that meet the requirements for designation accounting, and exceptional accounting is used for interest rate swap that meet the requirements for exceptional accounting.

Hedge instrument and hedge items	
[Hedge instruments]	[Hedge items]
Foreign exchange swaps	Foreign currency borrowings
Interest rate swaps	Borrowings

Hedge policy

The Company uses foreign exchange swaps and interest rate swaps to mitigate the foreign currency risk and the interest rate risk involved in procuring funds and hedge items are identified on an individual contract basis.

Method for evaluating the validity of hedges

For items covered by designation or exceptional accounting, the validity of the hedge is not evaluated.

[8] Other significant basis on preparation for consolidated financial statements

Consumption taxes

Consumption taxes are excluded from revenues and expenses accounts and consumption taxes unqualified for deduction for tax purposes for assets, etc. are reported as period expenses in the consolidated accounting period.

(Changes in Accounting Policy)

Application of the Accounting Standard for Retirement Benefits and its Guidance

The Company applied "Accounting Standard for Retirement Benefits" (ASBJ Statement No.26, May 27, 2012) and the "Guidance on the Accounting Standard for Retirement Benefits" (ASBJ Guidance No.25, May 17, 2012) effective the end of the fiscal year; except for the provisions specified under the main clause of Section 35 of the Accounting Standard for Retirement Benefits and the main clause of Section 67 of the Guidance on the Accounting Standard for Retirement Benefits. Under the new accounting policy, the amount of retirement benefit obligations minus plan assets is recorded as defined benefit liability, and the unrecognized actuarial gains and losses and unrecognized prior service costs were recognized in defined benefit liability (in case that the amount of plan assets exceeds retirement benefit obligation, it is recorded as defined benefit asset). In applying the Accounting Standard for Retirement Benefits and its Guidance, the Company follows the tentative treatment set out in Section 37 of Accounting Standard for Retirement Benefit. Consequently, the effects of the changes in accounting policies were recognized in remeasurements of defined benefit plans under accumulated other comprehensive income in the fiscal year ended March 31, 2014.

As a result, as of March 31, 2014, defined benefit asset of 98million yen was recorded while defined benefit liability of 4,042million yen was recorded respectively. Also, the above impact on accumulated other comprehensive income was to reduce the amount by 357million yen.

(Additional Information)

Accounting Treatment of Retirement Benefit Trust (Employee Stockholding Association Purchase-type)

The Company provides employee stockholding association with the Company's own stocks via trust with the purpose of improving employee's welfare and increasing their motivation for enhancement of the enterprise value. For the accounting treatment of stock benefit trust (Employee stockholding Association Purchase-type), the Company adopted earlier "Practical Solution on Transactions of Delivering the Company's Own Stock to Employees etc. through Trusts" (PITF No.30, December 25, 2013).

1) Outline of the Trust

"Stock Benefit Trust (Employee Stockholding Association Purchase-type)" (hereinafter "the Plan") is an incentive plan to return the merit of the stock price rise to all members of "NIPRO Employee Stockholding Association" (hereinafter "the Association").

The Company, as settlor, entered into "Stock Provision Trust Agreement (Employee Stockholding Association Purchase-type)" (hereinafter "the Trust Agreement") with Mizuho Trust and Banking Co., Ltd, as trustee under the plan. The trust set up under the trust agreement is referred as "the Trust". Also Mizuho Trust and Banking Co., Ltd entered into a custodial agreement with Trust and Custody Service Bank, Ltd (Trust Account E) (hereinafter "Trust Account E"), thus, the trust will be re-entrusted to Trust and Custody Service Bank, Ltd.

The Trust Account E acquires the number of the Company's stocks all at once in advance as the Association expects to acquire in five years, and sells off the stocks to the Associations. The remaining funds will be distributed to qualified members of the association when there are earnings resulting from an upward swing in stock price when the Trust terminates. Also the Company provides Mizuho Trust and Banking Co., Ltd with guarantee against the loans which would be used for the purchase of the stocks; therefore, the Company will pay back the loan when a loss is caused by drop in stock prices at the end of trust period.

2) Company's own stocks remaining in the trust

The Company recorded own stocks in the trust as treasury stocks under net assets at book value excluding associated costs in the trust. The book value of own stocks for the period ended March 31, 2014 was 1,080 million yen, and the number of the stocks was 1,187 thousand shares.

3) Aggregate book value of loan under gross price method

The value was 1,091 million yen for the period ended March 31, 2014.

(Notes to the Consolidated Balance Sheets)

	(Previous period)	(Current Period)
1) Pledged assets	32,330 mil.yen	38,205 mil.yen
2) Discounted notes receivable	37 mil.yen	35 mil.yen
3) Accounts related to unconsolidated subsidiaries and affiliate companies		
Investment securities (stock)	2,157 mil.yen	4,554 mil.yen
Other of investments and other assets (Investments in capital)	3,384 mil.yen	6,584 mil.yen
4) Accounting practices of notes with maturity date of March 31, 2013		

The balance sheet date for the year ended March 31, 2013 fell on a bank holiday. Consequently, notes with maturity date of March 31, 2013 were included in the following accounts.

	(Previous period)	(Current Period)
Notes-receivable trade	1,302 mil.yen	- mil.yen
Notes-payable trade	503 mil.yen	- mil.yen

(Notes to the Consolidated Statement of Income)

	(Previous period)	(Current Period)
Research and development expenditure included in selling general and administrative expenses and manufacturing cost.	6,464 mil.yen	7,890 mil.yen

(Notes to the Consolidated Statements of Shareholders' equity)

Previous period (From April 1, 2012 to March 31, 2013)

1. Sort and total numbers of shared issues

Sort of shares	Number of shares as of April 1, 2012	Increased numbers	Decreased numbers	Number of shares As of March 31, 2013
Common stock	171,459,479	-	-	171,459,479

2. Sort and numbers of treasury stock

Sort of shares	Number of shares as of April 1, 2012	Increased numbers	Decreased numbers	Number of shares As of March 31, 2013
Common stock	913,612	625	130	914,107

- (Note) 1. The increased numbers are of purchase of shares which number is less than unit amount,.
2. The decreased numbers are of selling of shares which number is less than unit amount.

3. Dividends

(1) Amount of dividends paid

Decision	Sort of shares	Total amount of dividends paid	Dividends per shares	Basis date	Effective date
June 28, 2012 at ordinary general shareholders' meeting	Common stock	Millions of yen 1,961	Yen 11.50	March 31, 2012	June 29, 2012
November 9, 2012 at board of directors meeting	Common stock	Millions of yen 2,046	Yen 12.00	September 30, 2012	December 10, 2012

(2) Dividends of basis date belonging to the consolidated accounting period to its effective date be in the next consolidated accounting period.

Scheduled Decision	Sort of shares	Proceeds of dividends	Total amount of dividends paid	Dividends per shares	Basis date	Effective date
June 26, 2013 at ordinary general shareholders' meeting	Common stock	Earned surplus	Millions of yen 2,643	Yen 15.50	March 31, 2013	June 27, 2013

Current period (From April 1, 2013 to March 31, 2014)

1. Sort and total numbers of shared issues

Sort of shares	Number of shares as of April 1, 2013	Increased numbers	Decreased numbers	Number of shares As of March 31, 2014
Common stock	171,459,479	-	-	171,459,479

2. Sort and numbers of treasury stock

Sort of shares	Number of shares as of April 1, 2013	Increased numbers	Decreased numbers	Number of shares As of March 31, 2014
Common stock	914,107	21,034,840	1,217,974	20,730,973

- (Notes)
- Number of the stocks increased during the period due to the following reasons; 19,834,000 shares by tender offer, 1,240 shares by purchase of odd-lot shares, 1,199,600 shares acquired by Trust Account E from the Company.
 - Number of the stocks decreased during the period due to the following reasons; 6,172 shares by exercise of yen denominated convertible bond due in 2015, 102 shares by sale of odd-lot shares, 1,199,600 shares sold by the Company to Trust Account E, 12,100 shares sold by Trust Account E to the Association.
 - Number of the stocks as of the end of the period included, 1,187,500 shares owned by Trust Account E.

3. Dividends

(1) Amount of dividends paid

Decision	Sort of shares	Total amount of dividends paid	Dividends per shares	Basis date	Effective date
June 26, 2013 at ordinary general shareholders' meeting	Common stock	Millions of yen 2,643	Yen 15.50	March 31, 2013	June 27, 2013
November 12, 2013 at board of directors meeting	Common stock	Millions of yen 2,411	Yen 16.00	September 30, 2013	December 9, 2013

- (2) Dividends of basis date belonging to the consolidated accounting period to its effective date be in the next consolidated accounting period.

Scheduled Decision	Sort of shares	Proceeds of dividends	Total amount of dividends paid	Dividends per shares	Basis date	Effective date
June 26, 2014 at ordinary general shareholders' meeting	Common stock	Earned surplus	Millions of yen 2,202	Yen 14.50	March 31, 2014	June 27, 2014

(Note) Total amount of dividends paid includes the dividend on shares owned by Trust Account E, 17 million yen.

(Segment Information)

[Segment Information]

1. Outline of reportable operating segments

Applied ASBJ Statement No.17 "The Accounting Standard for Disclosures of Segments of an Enterprise and Related Information", the reportable operating segments are components of an entity for which separate financial information is available and evaluated regularly by the board of director in determining the allocation of management resources and in assessing performance. We currently operate our business on a stand-alone basis with the divisional organization and evaluate the performance of sales and manufacture of each division regardless of their products. Accordingly, we divide our operations into 3 reportable operating segments on the basis of its main products: Medical-Related, Pharmaceuticals-Related and Glass-Related.

*Medical-Related

Domestic division sells injection- and infusion-related products, artificial organ-related products, highly functional products, dialysis-related products and diabetic-related products. In the global business division, head office plays the center role and place overseas sales and manufacturing base for medical equipment and glass products for medical purpose and sales injection- and infusion-related products, artificial organ-related products, diabetic-related products, and glass for vials and ampoules.

*Pharmaceutical-Related

Pharmaceutical business division sells container for combination products and sells pharmaceuticals from pharmaceutical companies on a consignment basis. Domestic subsidiaries sell and manufacture injectable drug, oral drugs and combination products (Kit injectable).

*Glass-Related

In the field of glass for medical purposes, we sell glass for vials and ampoules. In the field of glass & materials products, we sell glass for thermos bottles and glass for lighting purpose.

2. Method of calculating sales and profit by reportable operating segment

The accounting process of the segments follows the accounting principles and practices listed in Basis of Preparation for the Consolidated Financial Statements. Profit of the segment is based on operating income. Internal revenue and transfer to revenue between segments are based on the market realized price.

3. Information on amount of sales, profit or loss, assets and other items by reportable segment

FY2012 (From April 1, 2012 to March 31, 2013)

(Millions of yen)

	Reportable Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated financial statements (Note.3)
	Medical -Related	Pharma- ceutical -Related	Glass -Related	Total				
Net sales								
(1)Sales to third parties	169,971	66,212	4,602	240,785	234	241,020	-	241,020
(2)Inter-segment sales and transfers	1,277	6,906	490	8,674	45	8,719	(8,719)	-
Total	171,248	73,119	5,092	249,460	280	249,740	(8,719)	241,020
Segment profit	14,287	3,988	600	18,876	220	19,097	(7,726)	11,370
Segment assets	304,752	132,829	7,090	444,672	4,542	449,214	130,087	579,302
Other items								
(1) Depreciation and amortization	12,085	8,191	77	20,353	49	20,402	807	21,209
(2) Amortization of goodwill	2,835	(0)	-	2,834	-	2,834	-	2,834
(3) Increase in tangible and intangible fixed assets	26,365	10,340	9	36,715	-	36,715	1,281	37,997

- (Note)
1. "Other" is the business segment which is not included in the reporting segment and consist of real estate income and sales by headquarter.
 2. Adjustment is as follows.
 - (1) Adjustment for the segment profit of (7,726) million yen includes elimination of inter-segment transaction of (43) million yen and corporate cost of (7,683) million yen. Corporate cost consists primarily of sales, general and administrative expenses and research and development cost which do not belong to the reporting segment.
 - (2) Adjustment for the segment assets of 130,087million yen includes elimination of inter-segment transaction of (51,050) million yen and corporate assets of 181,138 million yen. Corporate assets consisted primarily of cash and deposit, investment securities, assets for development and assets for management division of head office which do not belong to the reporting segment.
 - (3) Adjustment for depreciation and amortization of 807 million yen is for corporate assets. Depreciation and amortization and increase in tangible and intangible fixed assets include long-term prepaid expenses.
 - (4) Adjustment for increase in tangible and intangible fixed assets is increase in corporate assets.
 3. Segment profit is adjusted to the operating income on the consolidated statements of income.

FY2013 (From April 1, 2013 to March 31, 2014)

(Millions of yen)

	Reportable Segment				Other (Note.1)	Total	Adjust- ment (Note.2)	Consolidated financial statements (Note.3)
	Medical -Related	Pharma- ceutical -Related	Glass -Related	Total				
Net sales								
(1)Sales to third parties	244,196	51,507	4,776	300,481	271	300,752	-	300,752
(2)Inter-segment sales and transfers	1,400	7,511	575	9,486	-	9,486	(9,486)	-
Total	245,596	59,019	5,351	309,967	271	310,239	(9,486)	300,752
Segment profit	17,695	8,013	556	26,265	216	26,481	(14,192)	12,289
Segment assets	368,330	137,193	7,561	513,084	4,495	517,580	102,074	619,654
Other items								
(4) Depreciation and amortization	15,203	8,777	86	24,067	46	24,114	1,036	25,151
(5) Amortization of goodwill	4,823	3	-	4,827	-	4,827	-	4,827
(6) Increase in tangible and intangible fixed assets	19,617	10,646	89	30,353	-	30,353	4,739	35,093

- (Note)
1. "Other" is the business segment which is not included in the reporting segment and consist of real estate income and sales by headquarter.
 2. Adjustment is as follows.
 - (1) Adjustment for the segment profit of (14,192) million yen includes elimination of inter-segment transaction of (2,483) million yen and corporate cost of (11,708) million yen. Corporate cost consists primarily of sales, general and administrative expenses and research and development cost which do not belong to the reporting segment.
 - (2) Adjustment for the segment assets of 102,074million yen includes elimination of inter-segment transaction of (65,201) million yen and corporate assets of 167,275 million yen. Corporate assets consisted primarily of cash and deposit, investment securities, assets for development and assets for management division of head office which do not belong to the reporting segment.
 - (3) Adjustment for depreciation and amortization of 1,036 million yen is for corporate assets. Depreciation and amortization and increase in tangible and intangible fixed assets include long-term prepaid expenses.
 - (4) Adjustment for increase in tangible and intangible fixed assets is increase in corporate assts.
 3. Segment profit is adjusted to the operating income on the consolidated statements of income.

4. Change in Reportable Segment

- (1) Effective from the first quarter period ended June 30,2013, the pharmaceutical product sales unit of Nipro Pharma Corporation has been integrated into the Company's Domestic Division so that we can enhance our management capability through close coordination between the three divisions: the Medical Devices Division, the Pharmaceutical Products Division, and the Glass and Materials Division. In accordance with this change, the sales unit, which had previously been categorized into the Pharmaceutical-Related segment, is reclassified to the Medical-Related segment.

The segment information for ther period ended March 31, 2013 after reclassification, except for sales to external customers, is not available to the public, because accurately and retrospectively extracting data for cost of sales and selling, general and administrative expenses is practically difficult. In addition, the segment information for the current quarter period under review based on the segments before the reclassification is not available to the public either, because it is practically difficult to obtain necessary information to prepare it.

Sales to the external customers for the period ended March 31, 2013, if prepared based on the segments before the reclassification, would have been 191,074 million yen for the Medical-Related segment and 45,109 million yen for the Pharmaceutical-Related segment.

- (2) Effective from the first quarter period ended June 30, 2013, Chengdu Pingyuan Nipro Pharmaceutical Packaging Co., Ltd., Jilin Nipro Jiaheng Pharmaceutical Packing Co., Ltd. and Anyang Nipro Changda Pharmaceutical Packaging Co., Ltd., which had previously been categorized into the Glass-Related segment, are reclassified to the Medical-Related segment, as a result of review and re-examination as part of our international management strategy.

The segment information for the period ended March 31, 2013 is prepared based on the reportable segment after the reclassification.

[Related Information]

FY2012 (From April 1, 2012 to March 31, 2013)

1. Information for each product and service

Disclosure is omitted as the same information is disclosed in segment information.

2. Information for each area

(1) Net sales

(Millions of yen)

Japan	America	Europe	Asia	Total
138,961	46,311	32,372	23,375	241,020

(2) Property, plant and equipment

(Millions of yen)

Japan	America	Europe	Asia	Total
102,525	12,199	7,869	52,107	174,702

3. Information about impairment loss on fixed assets by reportable segments

(Millions of yen)

Reportable segment			Total	Other	Total
Medical-Related	Pharmaceutical-Related	Glass-Related			
2	-	-	2	-	2

4. Information about unamortized balance of goodwill by reportable segment

(Millions of yen)

	Reportable segment			Total	Other	Total
	Medical-Related	Pharmaceutical-Related	Glass-Related			
Balance of the fiscal year-end	22,731	8	-	22,740	-	22,740

FY2013 (From April 1, 2013 to March 31, 2014)

1. Information for each product and service

Disclosure is omitted as the same information is disclosed in segment information.

2. Information for each area

(1) Net sales

(Millions of yen)

Japan	America	Europe	Asia	Total
174,860	56,887	40,434	28,570	300,752

(2) Property, plant and equipment

(Millions of yen)

Japan	America	Europe	Asia	Total
103,368	16,305	11,104	60,815	191,593

3. Information about impairment loss on fixed assets by reportable segments

(Millions of yen)

Reportable segment			Total	Other	Total
Medical-Related	Pharmaceutical-Related	Glass-Related			
1	-	-	1	-	1

4. Information about unamortized balance of goodwill by reportable segment

(Millions of yen)

	Reportable segment			Total	Other	Total
	Medical-Related	Pharmaceutical-Related	Glass-Related			
Balance of the fiscal year-end	28,476	17	-	28,493	-	28,493

(Per Share Information)

	Previous period (From April 1, 2012 to March 31, 2013)	Current period (From April 1, 2013 to March 31, 2014)
Net assets per share	703.47 yen	832.14 yen
Earnings per share	59.99 yen	18.19 yen
Diluted Earnings per share	54.12 yen	16.29 yen

Base of the calculation is as follow;

1. Net assets per share

	Previous period (As of March 31, 2013)	Current period (As of March 31, 2014)
Total net assets in B/S (million yen)	128,763	135,960
Amount to be deducted from total net assets in B/S (Million yen)		
Minority interests	8,789	10,533
Net assets related to the common stocks(million yen)	119,973	125,426
Common stocks issued (Thousands shares)	171,459	171,459
Treasury stocks of common stock (Thousands shares)	914	20,730
Number of common stocks utilized for computation of net assets per share (thousand shares)	170,545	150,728

2. Earnings per share and diluted earnings per share

	Previous period (From April 1, 2012 To March 31, 2013)	Current period (From April 1, 2013 To March 31, 2014)
Earnings per share		
Net income (Million yen)	10,231	2,861
Amount not attributed to the common stock (Million yen)	-	-
Net income related to the common stock (Million yen)	10,231	2,861
Average shares of the common stock during the period (Thousands shares)	170,545	157,291
Diluted earnings per share		
Net income adjustment (Million yen)	-	-
Number of common stockincreased Stock acquisiton right (thousand shares)	18,518	18,389
Overview of the potential shares not included in the computation of diluted earning per share because of not having a dilutive effect	-	-

(Material Subsequent Event)

N/A

(Omission of Disclosures)

We have omitted disclosures concerning, Lease trade, Related party transactions, Tax effected accounting, Financial instruments, Securities, Derivative transactions, Retirement Benefit Plan, Stock options, Assets Retirement Obligations, Investment and Rental property and Business Combination, considered materiality in necessity of disclosure in this summary report.

5. Non-consolidated Financial Statements

(1) [Non-consolidated Balance Sheets]

(Millions of yen)

	As of March 31, 2013	As of March 31, 2014
Assets		
Current Assets		
Cash and deposits	61,559	40,413
Notes receivable-trade	14,197	15,079
Accounts receivable-trade	46,913	62,214
Securities	—	20
Merchandise and finished goods	19,700	29,192
Work in process	4,227	3,214
Raw materials and supplies	4,039	3,518
Advance payments-trade	2,283	1,197
Prepaid expenses	185	275
Deferred tax assets	1,732	2,488
Short-term loans receivable from subsidiaries and affiliates	709	40
Accounts receivable-other	1,497	1,485
Consumption taxes receivable	507	1,123
Other	663	730
Allowance for doubtful accounts	(71)	(8)
Total current assets	158,147	160,985
Noncurrent assets		
Property, plant and equipment		
Buildings	38,356	39,411
Accumulated depreciation and impairment loss	(25,042)	(25,491)
Buildings, net	13,314	13,920
Structures	1,969	1,994
Accumulated depreciation and impairment loss	(1,517)	(1,565)
Structures, net	451	428
Machinery, equipment	50,409	51,337
Accumulated depreciation and impairment loss	(42,619)	(45,115)
Machinery equipment, net	7,790	6,222
Vehicles	96	95
Accumulated depreciation and impairment loss	(93)	(86)
Vehicles, net	3	8
Tools, furniture and fixtures	14,523	15,641
Accumulated depreciation and impairment loss	(13,003)	(13,775)
Tools, furniture and fixtures, net	1,520	1,865
Land	11,432	11,787
Lease assets	846	879
Accumulated depreciation	(406)	(493)
Lease assets, net	440	385
Construction in progress	282	516
Total property, plant and equipment	35,236	35,134

(Millions of yen)

	As of March 31, 2013	As of March 31, 2014
Intangible assets		
Goodwill	—	3,731
Patent right	25	14
Right of trademark	2	3
Software	668	924
Lease assets	539	429
Telephone subscription right	23	23
Other	281	409
Total intangible assets	1,541	5,537
Investments and other assets		
Investment securities	59,232	59,112
Stocks of subsidiaries and affiliates	139,564	157,859
Investments in capital	0	0
Investments in capital of subsidiaries and affiliates	36,593	37,646
Long-term loans receivable	3,398	3,338
Long-term loans receivable from subsidiaries and affiliates	2,731	6,870
Claims provable in bankruptcy, claims provable in rehabilitation and other	343	340
Long-term prepaid expenses	711	1,313
Deferred tax assets	8,918	7,566
Other	485	603
Allowance for doubtful accounts	(2,569)	(2,444)
Allowance for investment loss	(2,629)	(2,629)
Total investments and other assets	246,781	269,579
Total noncurrent assets	283,559	310,251
Total assets	441,707	471,237
Liabilities		
Current liabilities		
Notes payable-trade	10,614	12,262
Accounts payable-trade	21,986	33,124
Short-term loans payable	32,000	31,000
Current portion of long-term loans payable	30,659	36,161
Commercial papers	10,000	10,000
Current portion of bonds	—	3,000
Current portion of Convertible bond-type bonds with subscription rights to shares	—	14,895
Lease obligations	338	322
Accounts payable-other	3,795	12,044
Directors' bonuses payable	316	415
Accrued expenses	694	759
Income taxes payable	2,600	5,100
Advances received	25	12
Deposits received	126	61
Unearned revenue	—	45
Provision for bonuses	1,049	1,179
Provision for loss on business liquidation	1,954	2,438
Notes payable-facilities	1,994	764
Other	722	1,721
Total current liabilities	118,878	165,308

(Millions of yen)

	As of March 31, 2013	As of March 31, 2014
Noncurrent liabilities		
Bonds payable	43,000	42,000
Convertible bond-type bonds with subscription rights to shares	14,900	—
Long-term loans payable	125,417	130,173
Lease obligations	692	535
Long-term unearned revenue	—	84
Provision for retirement benefits	1,026	1,151
Provision for directors' retirement benefits	563	256
Provision for loss on litigation	218	218
Long-term guarantee deposited	1,172	1,567
Total noncurrent liabilities	186,990	175,987
Total liabilities	305,869	341,295
Net assets		
Shareholders' equity		
Capital stock	84,397	84,397
Capital surplus		
Legal capital surplus	635	635
Other capital surplus	0	53
Total capital surplus	636	688
Retained earnings		
Legal retained earnings	1,673	2,178
Other retained earnings		
Reserve for dividends	16	16
Reserve for advanced depreciation of noncurrent assets	98	98
General reserve	56,035	60,535
Retained earnings brought forward	7,518	8,802
Total retained earnings	65,340	71,630
Treasury stock	(865)	(17,999)
Total shareholders' equity	149,509	138,717
Valuation and translation adjustments		
Valuation difference on available-for-sale securities	(13,672)	(8,776)
Total valuation and translation adjustments	(13,672)	(8,776)
Total net assets	135,837	129,941
Total liabilities and net assets	441,707	471,237

(2) [Non-consolidated Statements of Income and Non-consolidated Statement of Comprehensive Income]

Non-consolidated Statements of Income

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Net sales		
Net sales of finished goods	115,892	157,191
Net sales of goods	28,792	31,041
Rent income of real estate	280	271
Total net sales	144,965	188,504
Cost of sales		
Beginning finished goods	15,620	13,965
Beginning goods	6,501	5,735
Cost of products manufactured	40,196	40,457
Purchase of finished goods	44,494	85,023
Cost of purchased goods	23,823	25,877
Cost of real estate rent	59	55
Total	130,696	171,115
Ending finished goods	13,965	23,265
Ending goods	5,735	5,927
Total cost of sales	110,995	141,923
Gross profit	33,969	46,581
Selling, general and administrative expenses	23,531	31,807
Operating income	10,438	14,774
Non-operating income		
Interest income	140	169
Dividends income	2,189	2,217
Foreign exchange gains	3,110	3,039
Other	478	505
Total non-operating income	5,918	5,931
Non-operating expenses		
Interest expenses	1,598	1,704
Interest on bonds	550	514
Other	237	402
Total non-operating expenses	2,385	2,621
Ordinary income	13,971	18,084
Extraordinary income		
Gain on sales of noncurrent assets	7	160
Gain on sales of subsidiaries and affiliates' stocks	2,506	—
State subsidy	—	610
Gain on sales of investment securities	—	1,303
Other	0	3
Total extraordinary income	2,514	2,077
Extraordinary losses		
Loss on retirement of noncurrent assets	128	260
Settlement package	214	—
Provision for loss on litigation	48	—
Loss on reduction of non-current assets	—	580
Provision for loss on business liquidation	—	483
Other	42	489
Total extraordinary losses	433	1,814
Income before income taxes	16,052	18,347
Income taxes-current	4,368	7,009
Income taxes-deferred	1,827	(7)
Total income taxes	6,196	7,002
Net income	9,856	11,345

(3) [Non-consolidated Statements of Shareholders' Equity]

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Shareholder's equity		
Capital		
Balance at beginning of year	84,397	84,397
Increase (decrease) during the period		
Net increase (decrease) during the period	—	—
Balance at end of year	84,397	84,397
Capital surplus		
Capital reserve		
Balance at beginning of year	635	635
Increase (decrease) during the period		
Net increase (decrease) during the period	—	—
Balance at end of year	635	635
Other capital surplus		
Balance at beginning of year	0	0
Increase (decrease) during the period		
Disposal of treasury stock	(0)	52
Net increase (decrease) during the period	(0)	52
Balance at end of year	0	53
Total capital surplus		
Balance at beginning of year	636	636
Increase (decrease) during the period		
Disposal of treasury stock	(0)	52
Net increase (decrease) during the period	(0)	52
Balance at end of year	636	688
Earned surplus		
Earned reserve		
Balance at beginning of year	1,272	1,673
Increase (decrease) during the period		
Provision of legal retained earnings	400	505
Net increase (decrease) during the period	400	505
Balance at end of year	1,673	2,178
Other earned reserve		
Reserve for dividends		
Balance at beginning of year	16	16
Increase (decrease) during the period		
Net increase (decrease) during the period	—	—
Balance at end of year	16	16

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Reserve for advanced depreciation of noncurrent assets		
Balance at beginning of year	98	98
Increase (decrease) during the period		
Net increase (decrease) during the period	—	—
Balance at end of year	98	98
General reserve		
Balance at beginning of year	53,035	56,035
Increase (decrease) during the period		
Provision of general reserve	3,000	4,500
Net increase (decrease) during the period	3,000	4,500
Balance at end of year	56,035	60,535
Earned surplus carried forward		
Balance at beginning of year	5,070	7,518
Increase (decrease) during the period		
Dividends of surplus	(4,007)	(5,054)
Net income	9,856	11,345
Provision of legal retained earnings	(400)	(505)
Provision of general reserve	(3,000)	(4,500)
Net increase (decrease) during the period	2,447	1,284
Balance at end of year	7,518	8,802
Total earned surplus		
Balance at beginning of year	59,492	65,340
Increase (decrease) during the period		
Dividends of surplus	(4,007)	(5,054)
Net income	9,856	11,345
Net increase (decrease) during the period	5,848	6,290
Balance at end of year	65,340	71,630
Treasury stock		
Balance at beginning of year	(864)	(865)
Increase (decrease) during the period		
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,043
Net increase (decrease) during the period	(0)	(17,134)
Balance at end of year	(865)	(17,999)

(Millions of yen)

	FY2012 (From April 1, 2012 to March 31, 2013)	FY2013 (From April 1, 2013 to March 31, 2014)
Total Shareholders' equity		
Balance at beginning of year	143,661	149,509
Increase (decrease) during the period		
Dividend of surplus	(4,007)	(5,054)
Net income	9,856	11,345
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,096
Net increase (decrease) during the period	5,847	(10,791)
Balance at end of year	149,509	138,717
Valuation and translation differences		
Valuation differences of available-for-sale securities		
Balance at beginning of year	(7,924)	(13,672)
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	(5,748)	4,895
Net increase (decrease) during the period	(5,748)	4,895
Balance at end of year	(13,672)	(8,776)
Total valuation and translation differences		
Balance at beginning of year	(7,924)	(13,672)
Increase (decrease) during the period		
Net increase (decrease) of the items other than shareholders' equity during the period	(5,748)	4,895
Net increase (decrease) during the period	(5,748)	4,895
Balance at end of year	(13,672)	(8,776)
Total net assets		
Balance at beginning of year	135,737	135,837
Increase (decrease) during the period		
Dividend of surplus	(4,007)	(5,054)
Net income	9,856	11,345
Acquisition of treasury stock	(0)	(18,178)
Disposal of treasury stock	0	1,096
Net increase (decrease) of the items other than shareholders' equity during the period	(5,748)	4,895
Net increase (decrease) during the period	99	(5,896)
Balance at end of year	135,837	129,941

6. Others

(1) Changes in Directors

1) Change in representative of the company

N/A

2) Change in other directors or statutory auditors

Candidate for directors to be newly assigned (Scheduled assignment date: June 26, 2014)

Director Yoshiko Tanaka
(Currently, President of Medi Hope Co., Ltd and adjunct teacher in Kobe Pharmaceutical University)

Note: Ms. Yoshiko Tanaka is a candidate for external director to be newly assigned.